Deferasirox + Deferoxamine (DFO)
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transfusion-dependent β-thalassemia Patients
Conditions
Transfusion-dependent β-thalassemia Patients, Cardiac Iron Overload
Trial Timeline
Jan 1, 2011 → Jun 1, 2014
NCT ID
NCT01459718About Deferasirox + Deferoxamine (DFO)
Deferasirox + Deferoxamine (DFO) is a phase 2 stage product being developed by Novartis for Transfusion-dependent β-thalassemia Patients. The current trial status is terminated. This product is registered under clinical trial identifier NCT01459718. Target conditions include Transfusion-dependent β-thalassemia Patients, Cardiac Iron Overload.
What happened to similar drugs?
1 of 4 similar drugs in Transfusion-dependent β-thalassemia Patients were approved
Approved (1) Terminated (0) Active (3)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01459718 | Phase 2 | Terminated |
Competing Products
8 competing products in Transfusion-dependent β-thalassemia Patients
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Deferasirox | Novartis | Phase 3 | 40 |
| Deferasirox dispersable tablet (DT) + Deferasirox film coated tablet (FCT) | Novartis | Phase 2 | 35 |
| Deferasirox granule formulation + Deferasirox DT formulation | Novartis | Phase 2 | 35 |
| Deferoxamine + Deferasirox | Novartis | Approved | 43 |
| Placebo Matching Mitapivat + Mitapivat | Agios Pharmaceuticals | Phase 3 | 38 |
| Placebo Matching Mitapivat + Mitapivat | Agios Pharmaceuticals | Phase 3 | 38 |
| SLN124 + Placebo | Silence Therapeutics | Phase 1 | 19 |
| SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo | Silence Therapeutics | Phase 1 | 11 |